Navigation Links
Week in Review in the Health Outcomes and Pharma Pricing Field from HealthEconomics.Com

Ponte Vedra Beach, Florida (PRWEB) February 15, 2013

The top news story available on HealthEconomics.Com explored results of a study by the European Consortium in Healthcare Outcomes (ECHOUTCOME) claiming that the QALY (quality-adjusted life years) has failed as a common metric for assessing cost-benefit of drug therapies. The findings have set off a controversial debate on the continued use of the QALY as a measure for deciding whether or not a drug will be reimbursed by payers or health systems. The QALY is used by NICE (the National Institute for Health and Clinical Excellence) for coverage decisions by the National Health Service in the United Kingdom, as well as by Canada and Australia. Generally if a treatment costs more than £20,000-30,000 per QALY, it would not be recommended as cost-effective by NICE.

The study findings caused a backlash of protests by UK-based experts, defending the current system and NICE called the study "limited". More details on the QALY debate can be found on HealthEconomics.Com News.

Another popular news story related to the Pharmacy Benefit Management (PBM) sector. Costco, the largest warehouse club chain in the United States, has entered into the PBM marketplace with the intent to offer services to small and medium-sized companies located near their warehouse stores. Currently, Express Scripts Holding and CVS Caremark dominate the PBM business. PBMs play a significant role in drug coverage decisions and can dramatically impact the success or failure of a pharmaceutical drug product’s success in the marketplace. For more on the impact of Costco on the PBM marketplace, visit the HealthEconomics.Com News portal.

Can the pharmaceutical industry’s reputation be fixed? John LaMattina, a contributing author to Forbes.Com, provides several suggestions for improving pharma’s image, including greater transparency with doctor payments and clinical trial data, improved marketing and detailing of drugs within established guidelines and regulations, as well as limiting television direct-to-consumer advertisements.

About HealthEconomics.Com ( A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.

News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Up to the Challenge: Careers in Science in the Midst of Drastic Change, According to Wysebridge Patent Bar Review
2. Sigma-Aldrich Corporation Will Hold Its Annual Business Review March 21, 2013
3. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
4. Wysebridge Patent Bar Review Discusses Major Changes To The Patent Bar Exam
5. New EMR Comparison Website Launches Crowdsourcing Electronic Medical Record Software Reviews and Comparisons
6. Independent Marketing Automation Software Expert gives Positive review on MindMatrix's platform, AMP
7. Global Metabolomics Market Reviewed & Forecast in New In-Demand Report Available at
8. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
9. Wysebridge Patent Bar Review Announces the Launch of News Blog
10. Review Module Headlines BSI 8.6 Release for Enterprise Biobank Software
11. The 2013 CES: Patents, Legislation Reform, and the Growing Market for Patent Attorneys and Agents Reviewed by Wysebridge
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical Engineering ... premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place ... the largest number of attendees in more than a decade. , “The ...
Breaking Biology Technology:
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):